The STAR of the DLC family

Journal of Receptors and Signal Transduction

Volumn 33, Issue 1, 2013, Pages 10-13

  El Sitt, Sally ^a   El Sibai, Mirvat ^a  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

DLC1; DLC2; DLC3; GAPs; Tumor suppressor

Indexed keywords

DELETED IN LIVER CANCER PROTEIN; DELETED IN LIVER CANCER PROTEIN 1; DELETED IN LIVER CANCER PROTEIN 2; DELETED IN LIVER CANCER PROTEIN 3; ETOPOSIDE; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; GUANOSINE TRIPHOSPHATE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STEROIDOGENIC ACUTE REGULATORY PROTEIN RELATED LIPID TRANSFER DOMAIN CONTAINING PROTEIN; STEROIDOGENIC ACUTE REGULATORY PROTEIN RELATED LIPID TRANSFER DOMAIN CONTAINING PROTEIN 13; UNCLASSIFIED DRUG;

ACTIN FILAMENT; AMINO TERMINAL SEQUENCE; APOPTOSIS; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL SHAPE; CELL SURVIVAL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FOCAL ADHESION; GLIOBLASTOMA; HUMAN; LIPID TRANSPORT; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ANIMALS; ENZYME ACTIVATION; GTPASE-ACTIVATING PROTEINS; HUMANS; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84873106587     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2012.752002     Document Type: Review

References (42)

1. Bishop A, Hall A. RhoGTPases and their effector proteins. Biochem J 2000;348:241-55.
2. Hall A, Nobes C. RhoGTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. Phil Trans R Soc Lond 2000;355:965-70. (Pubitemid 30613321)
3. Hwang SL, Hong YR, Sy WD, et al. Rac1 gene mutations in human brain tumours. Eur J Surg Oncol 2004;30:68-72. (Pubitemid 38180994)
4. Johnson DI. Cdc42: an essential Rho-type GTPase controlling eukaryotic cell polarity. Microbiol Mol Biol Rev 1999;63:54-105. (Pubitemid 29116087)
5. Burbelo PD, Drechsel D, Hall A. A conserved binding motif defines numerous candidate target proteins for both Cdc42 and Rac GTPases. J Biol Chem 1995;270:29071-4.
6. Adamson P, Paterson HF, Hall A. Intracellular localization of the P21rho proteins. J Cell Biol 1992;119:617-27.
7. Karlsson R, Pedersen ED, Wang Z, et al. RhoGTPase function in tumorigenesis. Biochim Biophys Acta 2009;1796:91-8.
8. Abecassis I, Olofsson B, Schmid M, et al. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res 2003;291:363-6.
9. Raftopoulou M, Hall A. Cell migration: RhoGTPases lead the way. Dev Biol 2004;265:23-32. (Pubitemid 38018819)
10. DerMardirossian C, Bokoch G. GDIs: central regulatory molecules in RhoGTPase activation. Trends Cell Biol 2005;15:356-63. (Pubitemid 40943524)
11. Lin M, van Golen K. Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treatment 2004;84:49-60. (Pubitemid 38388860)
12. Rittinger K, Walker PA, Eccleston JF, et al. Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP. Nature 1997;388:693-7. (Pubitemid 27366443)
13. Yau TO, Leung TH, Lam S, et al. Deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis. PLoS One 2009;4:e6566.
14. Ahmadian MR, Wiesmuller L, Lautwein A, et al. Structural differences in the minimal catalytic domains of the GTPaseactivating proteins p120GAP and neurofibromin. J Biol Chem 1996;271:16409-15. (Pubitemid 26236267)
15. Moon SY, Zheng Y. RhoGTPase-activating proteins in cell regulation. Trends Cell Biol 2003;13:13-22.
16. Gamblin SJ, Smerdon SJ. GTPase-activating proteins and their complexes. Curr Opin Struct Biol 1998;8:195-201. (Pubitemid 28221051)
17. Moskwa P, Paclet MH, Dagher MC, et al. Autoinhibition of p50 RhoGTPase-activating protein (GAP) is released by prenylated small GTPases. J Biol Chem 2009;280:6716-20. (Pubitemid 40341226)
18. Lamarche N, Hall A. GAPs for rho-related GTPases. Trends Genet 1994;10:436-40. (Pubitemid 24352650)
19. Kandpal RP. RhoGTPase activating proteins in cancer phenotypes. Curr Protein Pept Sci 2006;7:355-65.
20. Bernards A, Settleman J. GAP control: regulating the regulators of small GTPases. Trends Cell Biol 2004;14:377-85. (Pubitemid 38891707)
21. Tcherkezian J, Lamarche-Vane N. Current knowledge of the large RhoGAP family of proteins. Biol Cell 2007;99:67-86. (Pubitemid 46242033)
22. Kim TY, Vigil D, Der CJ, et al. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev 2009;28:77-83.
23. Qian X, Li G, Asmussen HK, et al. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA 2007;104:9012-17. (Pubitemid 47175428)
24. Li H, Fung KL, Jin DY, et al. Solution structures, dynamics, and lipid-binding of the sterile alpha-motif domain of the deleted in liver cancer 2. Proteins 2007;67:1154-66. (Pubitemid 46753960)
25. Liao YC, Lo SH. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol 2008;40:843-7. (Pubitemid 351329658)
26. Kwan JJ, Donaldson LW. The NMR structure of the murine DLC2 SAM domain reveals a variant fold that is similar to a four-helix bundle. BMC Struct Biol 2007;7:34.
27. Grise F, Bidaud A, Moreau V. RhoGTPases in hepatocellular carcinoma. Biochim Biophys Acta 2009;1795:137-51.
28. Plaumann M, Seitz S, Frege R, et al. Analysis of DLC-1 expression in human breast cancer. J Cancer Res Clin Oncol 2003;129:349-54. (Pubitemid 36963197)
29. Goodison S, Yuan J, Sloan D, et al. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res 2005;65:6042-53. (Pubitemid 40994388)
30. Wong CM, Yam J, Ching YP, et al. RhoGTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 2005;65:8861-8. (Pubitemid 41377375)
31. Durkin M, Yuan BZ, Zhou X, et al. DLC-1: a RhoGTPaseactivating protein and tumor suppressor. J Cell Mol Med 2007;11:1185-207.
32. Durkin ME, Ullmannova V, Guan M, et al. Deleted in liver cancer 3 (DLC-3), a novel RhoGTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene 2007;26:4580-9. (Pubitemid 47037045)
33. Salhia B, Tran NL, Chan A, et al. The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am J Pathol 2008;173:1828-38.
34. Kawai K, Kiyota M, Seike J, et al. START-GAP3/DLC3 is a GAP for RhoA and Cdc42 and is localized in focal adhesions regulating cell morphology. Biochem Biophys Res Commun 2007;364:783-9. (Pubitemid 350087871)
35. Ching YP, Wong CM, Chan SF, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003;278:10824-30.
36. Ng DC, Chan SF, Kok KH, et al. Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. FEBS Lett 2006;580:191-8. (Pubitemid 43005335)
37. Ullmannova V, Popescu NC. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol 2006;29:1127-32.
38. Leung TH, Ching YP, Yam JW, et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA 2005;102:15207-12. (Pubitemid 41513360)
39. Kawai K, Seike J, Iino T, et al. START-GAP2/DLC2 is localized in focal adhesions via its N-terminal region. Biochem Biophys Res Commun 2009;380:736-41.
40. Xiaorong L, Wei W, Liyuan Q, et al. Underexpression of deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma. BMC Cancer 2008;8:205.
41. de Tayrac M, Etcheverry A, Aubry M, et al. Integrative genomewide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer 2009;48:55-68.
42. Leung TH, Yam JW, Chan LK, et al. Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2- p70S6K signalling pathway. Liver Int 2010;30:1315-23.